Biosolvix

Biosolvix is a preclinical-stage biotechnology company focused on developing novel therapeutics for protein misfolding diseases, with a primary emphasis on transthyretin amyloidosis (ATTR). Leveraging structural biology insights from the laboratory of Dr. David Eisenberg at UCLA, the company designs specific capping molecules that bind to amyloid fibrils to prevent further growth and promote dissociation. Their lead programs aim to provide disease-modifying treatments for both hereditary and wild-type ATTR. By targeting the fundamental structural basis of toxic protein aggregates, Biosolvix seeks to address unmet needs in neurodegenerative and systemic amyloid diseases. The company utilizes a structure-based drug design platform to create highly specific inhibitors that stabilize the native state of proteins or disrupt existing aggregates.